eISSN: 1731-2515
ISSN: 0209-1712
Anestezjologia Intensywna Terapia
Current issue Archive About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors
Editorial System
Submit your Manuscript
Search
4/2021
vol. 53
 
Share:
Send email
Share:
abstract:
Letter to the Editor

Is the efficacy of remdesivir so different from that of lopinavir–ritonavir in severe COVID-19? The answer by real time-PCR: a narrative review

Tiago Isidoro Duarte
1
,
Cesar Vieira
1
,
Carlos Pimentel
1
,
Mariana Cascão
2
,
Marta Torre
2
,
Joaquim Santos-Lima
2
,
Tânia Sequeira
1
,
Nuno Germano
1
,
Rita Corte-Real
3
,
Luís Bento
2

  1. Polyvalent Intensive Care Unit, Hospital de Curry Cabral, Lisbon, Portugal
  2. Medical Emergency Unit, Hospital de São José, Lisbon, Portugal
  3. Department of Clinical Patology, Hospital de Curry Cabral, Lisbon, Portugal
Anestezjologia Intensywna Terapia 2021; 53, 4: 363–365
Online publish date: 2021/12/22
View full text Get citation
 
This letter discusses the efficacy of current antiviral therapy used in severe COVID-19 infection. Since the first severe cases were documented, several antiviral options have been studied as adjuncts to standard supportive care [1, 2]. Firstly, the combination of lopinavir–ritonavir resurrected from SARS and MERS outbreaks and soon abandoned after the publication of several trials like the randomized controlled trial RECOVERY, which concluded that it was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progression to invasive mechanical ventilation or death [3]. Remdesivir is currently the only antiviral agent approved for the treatment of COVID-19. It is recommended for use in hospitalized patients who require supplemental oxygen. However, it is not routinely recommended for patients who require mechanical ventilation due to the lack of data showing any benefit at this advanced stage of the disease [4–6].
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.